Full Press Release Details
IDEAYA Announces Nomination of Development Candidate IDE397 for MAT2A Synthetic Lethality Program Targeting MTAP Deletion Patient Population.
IDYA
IDEAYA Announces Nomination of Development Candidate IDE397 for MAT2A Synthetic Lethality Program Targeting MTAP Deletion Patient Population
Key Takeaway: IDEAYA Announces Nomination of Development Candidate IDE397 for MAT2A Synthetic Lethality Program Targeting MTAP Deletion Patient Population
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma